<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002100</url>
  </required_header>
  <id_info>
    <org_study_id>127A</org_study_id>
    <secondary_id>LCPL 92-1-28</secondary_id>
    <nct_id>NCT00002100</nct_id>
  </id_info>
  <brief_title>Phase I/II Study of Curdlan Sulfate</brief_title>
  <official_title>Phase I/II Study of Curdlan Sulfate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AJI Pharma USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To assess the safety and tolerance of curdlan sulfate, as well as its anti-HIV activity, in
      HIV-infected patients with CD4 T-lymphocytes less than 500 cells/mm3, using first single
      doses and then, after FDA review, daily doses for 7 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Phase I of the study, escalating single doses of intravenous curdlan sulfate are tested.
      In Phase II, curdlan sulfate is administered daily for 7 days. (NOTE: Phase I is completed.)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Curdlan sulfate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients must have:

          -  HIV seropositivity.

          -  No current AIDS-defining opportunistic infection, lymphoma, Kaposi's sarcoma, or other
             malignancy.

          -  CD4 count &lt; 500 cells/mm3.

          -  No critical illness that would shorten life expectancy to &lt; 16 weeks.

        Exclusion Criteria

        Concurrent Medication:

        Excluded:

          -  Antiretroviral or other experimental therapies.

          -  Anticoagulants.

          -  Steroids.

          -  Cytotoxic or immunosuppressive agents.

        Concurrent Treatment:

        Excluded:

          -  Radiotherapy.

        Patients with the following prior condition are excluded:

        History of heparin sensitivity.

        Prior Medication:

        Excluded within 1 month prior to study entry:

          -  Antiretroviral or other experimental therapies.

          -  Anticoagulants.

          -  Steroids.

          -  Cytotoxic or immunosuppressive agents.

        Prior Treatment:

        Excluded:

          -  Radiotherapy within 1 month prior to study entry. Active IV drug abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ViRx Inc</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gordon M, Guralnik M, Kaneko Y, Mimura T, Baker M, Lang W. A phase I study of curdlan sulfate--an HIV inhibitor. Tolerance, pharmacokinetics and effects on coagulation and on CD4 lymphocytes. J Med. 1994;25(3-4):163-80.</citation>
    <PMID>7996061</PMID>
  </reference>
  <verification_date>April 1994</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>curdlan sulfate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curdlan sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

